Recombinant attenuated Salmonella typhimurium carrying a plasmid co-expressing ENDO-VEGI151 and survivin siRNA inhibits the growth of breast cancer in vivo

Molecular Medicine Reports

Volumn 7, Issue 4, 2013, Pages 1215-1222

  Li, Zhe ^a   Yin, Pei Hao ^b   Yang, Sheng Sheng ^c   Li, Qian Yu ^a   Chang, Tao ^a   Fang, Lin ^a   Shi, Lin Xiang ^a   Fang, Guo En ^d  

^a TONGJI UNIVERSITY   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c Department of Biochemistry and Molecular Biology ^*  (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Anti angiogenensis; Attenuated Salmonella typhimurium; Breast cancer; Gene therapy; Survivin

Indexed keywords

ANTINEOPLASTIC AGENT; GREEN FLUORESCENT PROTEIN; SMALL INTERFERING RNA; SURVIVIN;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CONTROLLED STUDY; GENE TARGETING; GENE TRANSFER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SALMONELLA TYPHIMURIUM;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICE; PLASMIDS; RNA, SMALL INTERFERING; SALMONELLA TYPHIMURIUM; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 15; VACCINES, ATTENUATED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875233562     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1308     Document Type: Article

References (26)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Grammatikakis I, Zervoudis S and Kassanos D: Synopsis of new antiangiogenetic factors, mutation compensation agents, and monoclonal antibodies in target therapies of breast cancer. J BUON 15: 639-646, 2010.
3. Stoff-Khalili MA, Dall P and Curiel DT: Gene therapy for carcinoma of the breast. Cancer Gene Ther 13: 633-647, 2006.
4. Butler JM, Kobayashi H and Rafii S: Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer 10: 138-146, 2010.
5. Weigand M, Hantel P, Kreienberg R and Waltenberger J: Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis 8: 197-204, 2005.
6. Li Z, Yang S, Chang T, Cao X, Shi L and Fang G: Anti-angiogenesis and anticancer effects of a plasmid expressing both ENDO-VEGI151 and small interfering RNA against survivin. Int J Mol Med 29: 485-490, 2012.
7. Cao S, Cripps A and Wei MQ: New strategies for cancer gene therapy: progress and opportunities. Clin Exp Pharmacol Physiol 37: 108-114, 2010.
8. Jimeno A and Hidalgo M: Multitargeted therapy: can promiscuity be praised in an era of political correctness? Crit Rev Oncol Hematol 59: 150-158, 2006.
9. Zhang Y, Qu ZH, Cui M, Guo C, Zhang XM, Ma CH and Sun WS: Combined endostatin and TRAIL gene transfer suppresses human hepatocellular carcinoma growth and angiogenesis in nude mice. Cancer Biol Ther 8: 466-473, 2009.
10. Yu B, Zhang Y, Zhan Y, Zha X, Wu Y, Zhang X, Dong Q, Kong W and Yu X: Co-expression of herpes simplex virus thymidine kinase and Escherichia coli nitroreductase by an hTERT-driven adenovirus vector in breast cancer cells results in additive anti-tumor effects. Oncol Rep 26: 255-264, 2011.
11. Abdollahi A and Folkman J: Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 13: 16-28, 2010.
12. Miles DW, Chan A, Dirix LY, et al: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28: 3239-3247, 2010.
13. Robert NJ, Diéras V, Glaspy J, et al: RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29: 1252-1260, 2011.
14. Kerbel RS: Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer. Breast 18 (Suppl 3): S41-S47, 2009.
15. Leite de Oliveira R, Hamm A and Mazzone M: Growing tumor vessels: more than one way to skin a cat -implications for angiogenesis targeted cancer therapies. Mol Aspects Med 32: 71-87, 2011.
16. Pang RW and Poon RT: Clinical implications of angiogenesis in cancers. Vasc Health Risk Manag 2: 97-108, 2006.
17. Eichhorn ME, Kleespies A, Angele MK, Jauch KW and Bruns CJ: Angiogenesis in cancer: molecular mechanisms, clinical impact. Langenbecks Arch Surg 392: 371-379, 2007.
18. Carrasco RA, Stamm NB, Marcusson E, Sandusky G, Iversen P and Patel BK: Antisense inhibition of survivin expression as a cancer therapeutic. Mol Cancer Ther 10: 221-232, 2011.
19. Rice C and Huang LE: From antiangiogenesis to hypoxia: current research and future directions. Cancer Manag Res 3: 9-16, 2010.
20. Peng XH, Karna P, Cao Z, Jiang BH, Zhou M and Yang L: Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem 281: 25903-25914, 2006.
21. Liu C, Liang B, Wang Q, Wu J and Zou MH: Activation of AMP-activated protein kinase alpha1 alleviates endothelial cell apoptosis by increasing the expression of anti-apoptotic proteins Bcl-2 and survivin. J Biol Chem 285: 15346-15355, 2010.
22. Gardlik R and Fruehauf JH: Bacterial vectors and delivery systems in cancer therapy. IDrugs 13: 701-706, 2010.
23. Gardlik R, Behuliak M, Palffy R, Celec P and Li CJ: Gene therapy for cancer: bacteria-mediated anti-angiogenesis therapy. Gene Ther 18: 425-431, 2011.
24. Ji K, Wang B, Shao YT, et al: Synergistic suppression of prostatic cancer cells by coexpression of both murine double minute 2 small interfering RNA and wild-type p53 gene in vitro and in vivo. J Pharmacol Exp Ther 338: 173-183, 2011.
25. Zhu X, Zhou P, Cai J, Yang G, Liang S and Ren D: Tumor antigen delivered by Salmonella III secretion protein fused with heat shock protein 70 induces protection and eradication against murine melanoma. Cancer Sci 101: 2621-2628, 2010.
26. Lu XL, Jiang XB, Liu RE and Zhang SM: The enhanced anti-angiogenic and antitumor effects of combining flk1-based DNA vaccine and IP-10. Vaccine 26: 5352-5357, 2008.